title: Preparation and in vitro/in vivo evaluation of microparticle formulations containing meloxicam.
abstract: In this study, we have formulated chitosan-coated sodium alginate microparticles containing meloxicam (MLX) and aimed to investigate the correlation between in vitro release and in vivo absorbed percentages of meloxicam. The microparticle formulations were prepared by orifice ionic gelation method with two different sodium alginate concentrations, as 1% and 2% (w/v), in order to provide different release rates. Additionally, an oral solution containing 15 mg of meloxicam was administered as the reference solution for evaluation of in vitro/in vivo correlation (ivivc). Following in vitro characterization, plasma levels of MLX and pharmacokinetic parameters [elimination half-life (t(1/2)), maximum plasma concentration (C(max)), time for C(max) (t(max))] after oral administration to New Zealand rabbits were determined. Area under plasma concentration-time curve (AUC(0-∞)) was calculated by using trapezoidal method. A linear regression was investigated between released% (in vitro) and absorbed% (in vivo) with a model-independent deconvolution approach. As a result, increase in sodium alginate content lengthened in vitro release time and in vivo t(max) value. In addition, for ivivc, linear regression equations with r(2) values of 0.8563 and 0.9402 were obtained for microparticles containing 1% and 2% (w/v) sodium alginate, respectively. Lower prediction error for 2% sodium alginate formulations (7.419 ± 4.068) compared to 1% sodium alginate formulations (9.458 ± 5.106) indicated a more precise ivivc for 2% sodium alginate formulation.
authors.affiliation: Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey. ehakan@hacettepe.edu.tr
authors.forename: Hakan
authors.initials: H
authors.lastname: Eroglu
authors.forename: Nihan
authors.initials: N
authors.lastname: Burul-Bozkurt
authors.forename: Serdar
authors.initials: S
authors.lastname: Uma
authors.forename: Levent
authors.initials: L
authors.lastname: Oner
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D004353:Drug Evaluation, Preclinical / Q000379:methods; D000077239:Meloxicam; D008863:Microspheres; D011817:Rabbits; D013843:Thiazines / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism*; D013844:Thiazoles / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism*
chemical_list: D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam
references.citation: Drug Dev Ind Pharm. 2003 Jul;29(6):713-24
references.pmid: 12889789
references.citation: Pharm Res. 1998 Mar;15(3):466-73
references.pmid: 9563079
references.citation: Int J Pharm. 2007 May 24;336(2):329-37
references.pmid: 17223290
references.citation: Int J Pharm. 2002 Jul 8;241(1):87-95
references.pmid: 12086724
references.citation: Biopharm Drug Dispos. 2000 Nov;21(8):321-6
references.pmid: 11514951
references.citation: J Control Release. 2003 Feb 14;88(1):147-57
references.pmid: 12586512
references.citation: Biol Pharm Bull. 2008 Oct;31(10):1946-51
references.pmid: 18827360
references.citation: J Pharm Sci. 2001 Aug;90(8):1176-85
references.pmid: 11536222
references.citation: Eur J Pharm Sci. 2005 Mar;24(4):305-13
references.pmid: 15734297
references.citation: Int J Pharm. 2002 Jan 31;232(1-2):225-34
references.pmid: 11790506
references.citation: J Chromatogr B Biomed Sci Appl. 2000 Feb 11;738(2):431-6
references.pmid: 10718662
references.citation: J Pharm Pharmacol. 2007 Jul;59(7):971-6
references.pmid: 17637192
references.citation: J Microencapsul. 2002 Mar-Apr;19(2):173-80
references.pmid: 11837972
references.citation: Adv Exp Med Biol. 1997;423:269-88
references.pmid: 9269503
references.citation: Clin Pharmacokinet. 1999 Feb;36(2):115-26
references.pmid: 10092958
references.citation: J Pharm Sci. 2005 Sep;94(9):1949-56
references.pmid: 16052544